CLS Americas Announces Kearney Urology Center will use its TRANBERG Laser to Provide Focal Laser Ablation Treatments to Prostate Cancer Patients

New TRANBERG Mobile Service Enables Urologists to Provide Minimally Invasive, Image-guided, Laser Ablation Treatments to Patients without Capital Expenditure

IRVINE, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that Kearney Urology Center, PC, a Nebraska Professional Corporation located in Kearny, NE, has signed a Mobile Services Agreement to treat prostate cancer patients using CLS products. Under the agreement, CLS provides its FDA 510(k) cleared, TRANBERG™ Thermal Therapy System in a bundled service offering, with consumable accessories, training, and on-site clinical and technical staff support to Kearney Urology physicians and staff during procedures.

In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men. Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.

“We are excited to begin offering this new minimally invasive focal laser ablation treatment to our patients with low-to-intermediate risk prostate cancer. The CLS Laser is very precise, easy to operate, and the treatment workflow is similar to prostate cryotherapy procedures,” stated Garrett D. Pohlman, M.D., Kearney Urology Center. “CLS’s Mobile Service and support program will allow us to begin treating patients quickly without any capital equipment expense. This benefits both our patients and our clinic.”

The Kearney Urology Center PC provides Pediatric and Adult Urologic Care featuring Board Certified Urologists and Robotic Surgery Specialists.

“CLS Americas is pleased to provide the Kearney Urology Center, PC with the training, use, and clinical support of our TRANBERG focal laser ablation system,” stated Michael Magnani, president of CLS Americas. “We are excited to be partnering with an emerging regional provider of advanced urological treatments and an early adopter of promising new medical devices and treatments.”

TRANBERG™ Thermal Therapy System
The TRANBERG Thermal Therapy System can be configured for MR/US fusion-guided procedures using real-time tissue temperature measurements for precise therapy and ablation control. It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, tissue temperature probes, and procedure-specific accessories. The TRANBERG system can be deployed in either a transperineal or transrectal approach. The TRANBERG system is 510(k) cleared for soft tissue ablation, such as prostate. A TRANBERG FLA Animation Video of the system and procedure is available to watch.

About CLS Americas, Inc.
Clinical Laserthermia Systems Americas Inc, based in Irvine, CA, is responsible for the sales, commercial development, operations and clinical support for the TRANBERG™ Thermal Therapy System and accessories for the US urology market. The powerful system provides minimally invasive, focal laser ablation treatments using MR or MR US Fusion for image guidance and has received FDA 510(k) clearance in the US for soft tissue ablation, such as prostate tumors.

CLS Americas is a subsidiary of Clinical Laserthermia Systems AB (publ) headquartered in Lund, Sweden, which has subsidiaries in Germany, the US and Singapore.  For more information about CLS, please visit the Company's website:  CLS Americas Contact:  Phone: +1 (949) 504-5440, E-mail:


Contact Data